BridgeBio Oncology Therapeutics, Inc. BBOT
2.56 USD +0.36 (+16.36%)
At closeNov 12, 2026, 7:45 AM EST
2.64 +0.08 +3.13%
Pre-market · Nov 12, 7:45 AM ET
2.25 Day range 2.65
1.98 52-week range 14.87
- YTD
- -79.55%
- 1 year
- -79.92%
News
benzinga.com These Analysts Cut Their Forecasts On BridgeBio Oncology After Q3 Results BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) on Tuesday posted a narrower-than-expected loss for the third quarter.
benzinga.com These Analysts Cut Their Forecasts On BridgeBio Oncology After Q3 Results BridgeBio Oncology beat Q3 loss estimates, shares jumped 18%, while analysts cut price targets to $9 and $15.
benzinga.com Piper Sandler Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $15 Piper Sandler analyst Biren Amin maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $21 to $15.
benzinga.com Wedbush Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $9 Wedbush analyst David Nierengarten maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $25 to $9.- benzinga.com BridgeBio Oncology Q3 EPS $(0.43) Beats $(0.69) Estimate BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.69) by 37.68 percent. This is a 58.25 percent increase over losses of…
globenewswire.com BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-11818 and BBO-10203 combination cohorts…
benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13 Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.- benzinga.com Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16 Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON)…
benzinga.com Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27 Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
benzinga.com Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20 Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
benzinga.com Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22 Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…- benzinga.com Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15 Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.
- benzinga.com Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
benzinga.com Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly…- benzinga.com JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25 JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.
benzinga.com BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over…
benzinga.com Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-expected earnings. Other big gainers: PRME, BZH, WULF, VRXA, BABA, ACDC, KC, PARR, SWMR, BBOT, KEX- benzinga.com JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27 JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.
- benzinga.com Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22 Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $22.
benzinga.com BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY, BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent decrease over losses of $(54.23) per share from the same period last year.
benzinga.com This Arxis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. For full rating changes, check analyst ratings page. ARXS: Buy, $53 PT. See analyst views.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23 Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.
- benzinga.com BridgeBio Oncology Therapeutics Presents New Preclinical Data For BBO-11818 Inhibitor At American Association For Cancer Research Annual Meeting 2026 BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data for BBO-11818, a…
- benzinga.com BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran CEO, Idan Elmelech COO, Effective April 25; Neil Kumar Appointed Executive Chairman BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Pedro J. Beltran,…
- benzinga.com BridgeBio Oncology Therapeutics Reveals Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models At The AACR Annual Meeting 2026; BBO-10203 Physically And Allosterically Disrupts The Interaction Between RAS And PI3Kα, Leading To Signaling Inhibition Without Inhibiting The Kinase Activity of PI3Kα And With No Observed Hyperglycemia BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data in an oral…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com FDA Grants BridgeBio Oncology Therapeutics Fast Track Designation To BBO-11818 BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumorsUpdated Phase 1 clinical data are expected…
- benzinga.com BridgeBio Announces Publication Of Preclinical Data Describing Discovery Of BBO-11818, panKRAS Inhibitor Targeting KRAS In ON And OFF States For Patients With KRAS Mutant Cancers BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS…
benzinga.com This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session